TABLE 7-2, Adverse Events Discovered During an FDA Inspection - The Clinical Utility of Compounded Bioidentical Hormone Therapy

Adverse Event	Number of Events Identified
Acne	11
Amenorrhea	1
Breast cancer	154
Cellulitis	529
Deep vein thrombosis	40
Endometrial cancer	21
Enlarged clitoris	6
Facial hair	7
Hair loss	30
Heart attack	37
Other complications	427
Pellet extrusions	2,335
Prostate cancer	25
Stroke	31
Voice deepening	2

From: 7, The Safety and Effectiveness of Compounded Bioidentical Hormone Therapy

Cover of The Clinical Utility of Compounded Bioidentical Hormone Therapy

The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; Jackson LM, Parker RM, Mattison DR, editors.

Washington (DC): National Academies Press (US); 2020 Jul 1.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

TABLE 7-2Adverse Events Discovered During an FDA Inspection